Erfonrilimab (Anti-CTLA4 & PD-L1)
Product Specifications
CAS Number
2367013-69-0
Synonyms
KN 046
Target
PD-1/PD-L1
Applications
Apoptosis
Additionnal Information
Erfonrilimab is a humanized bispecific monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. It is used to treat solid tumors and exhibits promising efficacy in advanced non-small cell lung cancer (NSCLC) patients who had experienced failure or intolerance to prior platinum-based chemotherapy. MW: 107.44 KD.
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880181-500 1x 500 µL
CD59 (heavy chain of Protectin) (BRA-10G), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680149-100 1x 100 µL
CD106 / VCAM1 (1.4C3), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402848-100 1x 100 µL
Fibronectin (Fn-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
